Concurrent Use of Opioids and Benzodiazepines (COB- NQF Endorsement Status Endorsed NQF ID 3389 Measure Type Process Measure Content Last Updated 2021-06-30 Info As Of Not Available Properties Description Percentage of Medicaid beneficiaries age 18 and older with concurrent use of prescription opioids and benzodiazepines. Numerator The number of individuals from the denominator with: Two or more prescription claims for any benzodiazepine (Table COB-B) with unique dates of service, AND Concurrent use of opioids and benzodiazepines for 30 or more cumulative days. Table COB-B. Benzodiazepinesa Benzodiazepine Medications Alprazolam Chlordiazepoxide Clobazam Clonazepam Clorazepate Diazepam Estazolam Flurazepam Lorazepam Midazolam Oxazepam Quazepam Temazepam Triazolam Denominator Age 18 and older as of January 1 of the measurement year. Identify individuals with 2 or more prescriptions for opioids (Table COB-A) with unique dates of service, for which the sum of the days supply is 15 or more during the measurement year. Exclude individuals who met at least one of the following during the Report Generated: Sun Oct 03 03:11:28 EDT 2021 | Page 1 Concurrent Use of Opioids and Benzodiazepines (COB- measurement year: Hospice Cancer Diagnosis Table COB-A. Opioid Medications Opioid Medications Buprenorphinec Butorphanol Codeine Dihydrocodeine Fentanyld Hydrocodone Hydromorphone Levorphanol Meperidine Methadone Morphine Opium Oxycodone Oxymorphone Pentazocine Tapentadol Tramadol Denominator Exclusions Beneficiaries with cancer are excluded from this measure and may be identified using the ICD-10 codes in Table COB-C, available at https://www.medicaid.gov/license-agreement.html file=%2Fmedicaid%2Fquality-of-care%2Fdownloads%2F2018-adult-non-hedis- value-set-directory.zip. The cancer exclusion criterion is for beneficiaries with a diagnosis code for cancer during the measurement year. Their initial diagnosis may have occurred previously; however, the diagnosis code for cancer must be present Rationale Not Available Evidence Not Available Developer/Steward Steward Pharmacy Quality Alliance Contact Not Available Measure Developer Not Available Report Generated: Sun Oct 03 03:11:28 EDT 2021 | Page 2 Concurrent Use of Opioids and Benzodiazepines (COB- Development Stage Fully Developed Characteristics Measure Type Process Meaningful Measure Area Not Available Healthcare Priority Making Care Safer by Reducing Harm Caused in the Delivery of Care eCQM Spec Available No NQF Endorsement Status Endorsed NQF ID 3389 Last NQF Update 2020-10-19 Target Population Age 18+ Target Population Age (High) Not Available Target Population Age (Low) 18 Reporting Level Not Available Conditions Substance Abuse Subconditions Opioid Dependency Care Settings Hospital Outpatient; Other; Outpatient Groups Core Measure Set Medicaid Adult Core Set Measure Group Group Identifier Adult Core Set Report Generated: Sun Oct 03 03:11:28 EDT 2021 | Page 3 Concurrent Use of Opioids and Benzodiazepines (COB- Measure Links Measure Program: Medicaid Info As Of Not Available Program / Model Notes Data Sources Claims Data Purposes Not Available Quality Domain Not Available Reporting Frequency Not Available Impacts Payment No Reporting Status Active Data Reporting Begin Date 2018-10-01 Data Reporting End Date Not Available Measure Program Links https://www.medicaid.gov/ Report Generated: Sun Oct 03 03:11:28 EDT 2021 | Page 4.